key: cord-0925138-rf589xaf
authors: Raviv, Sivan Arber; Alyan, Mohammed; Egorov, Egor; Zano, Agam; Harush, Moshit Yaskin; Pieters, Calvin; Korach-Rechtman, Hila; Saadya, Adi; Kaneti, Galoz; Nudelman, Igor; Farkash, Shai; Flikshtain, Ofri Doppelt; Mekies, Lucy N.; Koren, Lilach; Gal, Yoav; Dor, Ella; Shainsky, Janna; Shklover, Jeny; Adir, Yochai; Schroeder, Avi
title: Lung targeted liposomes for treating ARDS
date: 2022-03-28
journal: J Control Release
DOI: 10.1016/j.jconrel.2022.03.028
sha: 856a6b3ce2412d3f36ad7f0b5e124b54cf49df79
doc_id: 925138
cord_uid: rf589xaf

Acute Respiratory Distress Syndrome (ARDS), associated with Covid-19 infections, is characterized by diffuse lung damage, inflammation and alveolar collapse that impairs gas exchange, leading to hypoxemia and patient’ mortality rates above 40%. Here, we describe the development and assessment of 100-nm liposomes that are tailored for pulmonary delivery for treating ARDS, as a model for lung diseases. The liposomal lipid composition (primarily DPPC) was optimized to mimic the lung surfactant composition, and the drug loading process of both methylprednisolone (MPS), a steroid, and N-acetyl cysteine (NAC), a mucolytic agent, reached an encapsulation efficiency of 98% and 92%, respectively. In vitro, treating lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages with the liposomes decreased TNFα and nitric oxide (NO) secretion, while NAC increased the penetration of nanoparticles through the mucus. In vivo, we used LPS-induced lung inflammation model to assess the accumulation and therapeutic efficacy of the liposomes in C57BL/6 mice, either by intravenous (IV), endotracheal (ET) or IV plus ET nanoparticles administrations. Using both administration methods, liposomes exhibited an increased accumulation profile in the inflamed lungs over 48 h. Interestingly, while IV-administrated liposomes distributed widely throughout the lung, ET liposomes were present in lungs parenchyma but were not detected at some distal regions of the lungs, possibly due to imperfect airflow regimes. Twenty hours after the different treatments, lungs were assessed for markers of inflammation. We found that the nanoparticle treatment had a superior therapeutic effect compared to free drugs in treating ARDS, reducing inflammation and TNFα, IL-6 and IL-1β cytokine secretion in bronchoalveolar lavage (BAL), and that the combined treatment, delivering nanoparticles IV and ET simultaneously, had the best outcome of all treatments. Interestingly, also the DPPC lipid component alone played a therapeutic role in reducing inflammatory markers in the lungs. Collectively, we show that therapeutic nanoparticles accumulate in inflamed lungs holding potential for treating lung disorders. SIGNIFICANCE: In this study we compare intravenous versus intratracheal delivery of nanoparticles for treating lung disorders, specifically, acute respiratory distress syndrome (ARDS). By co-loading two medications into lipid nanoparticles, we were able to reduce both inflammation and mucus secretion in the inflamed lungs. Both modes of delivery resulted in high nanoparticle accumulation in the lungs, intravenously administered nanoparticles reached lung endothelial while endotracheal delivery reached lung epithelial. Combining both delivery approaches simultaneously provided the best ARDS treatment outcome.

through the mucus. In vivo, we used LPS-induced lung inflammation model to assess the accumulation and therapeutic efficacy of the liposomes in C57BL/6 mice, either by intravenous (IV), endotracheal (ET) or IV plus ET nanoparticles administrations.

Using both administration methods, liposomes exhibited an increased accumulation profile in the inflamed lungs over 48 hours. Interestingly, while IV-administrated liposomes distributed widely throughout the lung, ET liposomes were present in lungs parenchyma but were not detected at some distal regions of the lungs, possibly due to imperfect airflow regimes.

Twenty hours after the different treatments, lungs were assessed for markers of inflammation.

We found that the nanoparticle treatment had a superior therapeutic effect compared to free drugs in treating ARDS, reducing inflammation and TNFα, IL-6 and IL-1β cytokine secretion in bronchoalveolar lavage (BAL), and that the combined treatment, delivering nanoparticles IV and ET simultaneously, had the best outcome of all treatments. Interestingly, also the DPPC lipid component alone played a therapeutic role in reducing inflammatory markers in the lungs. Collectively, we show that therapeutic nanoparticles accumulate in inflamed lungs holding potential for treating lung disorders.

Keywords: Liposome, pulmonary, ARDS, Covid-19, COPD, lung inflammation, mucus, nanotechnology

Lung inflammation is characteristic in various respiratory diseases and injuries, such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, long COVID, and acute respiratory distress syndrome (ARDS) diagnosis 1 .

ARDS is an inflammatory diffused form of lung injury that leads to increased pulmonary vascular permeability, resulting in secretion of interstitial fluids in the alveolar space and their collapse, making oxygen exchange difficult or impossible 2 . ARDS etiologies include, among others, severe trauma and sepsis, and a recent notable cause is SARS-CoV-2 infections (COVID-19) 3, 4 . Patients with ARDS are severely hypoxemic, and existing therapy is mostly supportive but not curative, with mortality rates exceeding 40% 5 . Patients with ARDS tend to progress through three pathologic stages: the early exudative phase, the fibroproliferative phase, and the fibrotic phase. The lipopolysaccharide (LPS) insult model stimulates the exudative stage, which includes a nonspecific reaction to lung injury, interstitial edema, accompanied by acute and chronic inflammation 2,6,7 . J o u r n a l P r e -p r o o f Inflammation involves the activation of numerous immune cell types including neutrophils and macrophages 1, 8, 9 . While neutrophils perform extravasation towards the infected site to fight off invaders by degranulation and through phagocytotic behavior, pro-inflammatory macrophages produce cytokines such as TNF-α, IL-1β and IL-6 in response to bacterial components, such as LPS [10] [11] [12] [13] . Moreover, in response to such stimuli, macrophages release reactive oxygen species (ROS) and produce nitric oxide (NO), which regulate inflammatory cells and protect the organism from potential dangers 14, 15 . NO levels were used as an additional parameter for macrophage activation in vitro. The detection of cytokines in bronchoalveolar lavage (BAL) fluid is well corelated with the severity of inflammation in disease models, as verified by histological analyses 16 .

Glucocorticoids, such as methylprednisolone (MPS) are used widely for treating lung inflammation [17] [18] [19] . Glucocorticoids diffuse through cell membranes leveraging amphipathic properties and cellular receptors. In the cytoplasm glucocorticoids bind glucocorticoid receptors reducing proinflammatory cytokine synthesis and inhibiting fibroblast proliferation and collagen synthesis via non-genomic and genomic pathways 20, 21 . In addition, steroids decrease NO synthase in macrophages, leading to decreased NO secretion 22 .

MPS was evaluated for treating early ARDS and showed positive therapeutic outcomes and improved survival 17, 18 Methylprednisolone treatment of COVID-19 patients resulted in higher oxygenation index 19 , with doses ranging from 1 mg/kg-body-weight per day to single doses of 40-500 mg 20 . However, systemic and prolonged administration of glucocorticoids is associated with severe side effects, such as interference with wound healing process, inhibition of effector cells in fighting active infections and other myopathic, cardiovascular and dermatologic side effects 23, 24 .

Additionally, a potential agent we tested for treating ARDS is N-acetyl cysteine (NAC) to treat mucus hypersecretion during inflammation that impairs blood-gas exchange. NAC is a mucolytic agent that reduces connecting disulfide bonds in mucus, thereby reducing mucus viscosity and accelerating mucus plugs removal [25] [26] [27] . Another therapeutic effect of NAC is as an antioxidant and decreasing the reactive oxygen species (ROS) 28, 29 . A meta-analysis of ARDS patients that were treated with NAC found shorter hospitalization periods in the intensive care unit. Dose for NAC treatments varied from 40-210 mg/kg/day over 3-10 days 30 31 . By oral administration, the bioavailability of NAC is less than 10% due to extensive firstpass metabolism 32 .

J o u r n a l P r e -p r o o f

The combination of NAC and corticosteroids was described in COPD patients, resulting in an improved oxidant burden 33 . Here, we tested an MPS and NAC combination in an ARDS model.

Drug concentrations at the target site following intravenous (IV) administration can be below the therapeutic window, therefore, to increase drug concentrations and bioavailability at the target site, decrease side effects, and prolonged the retention time of the drug at the target tissue we encapsulated drugs in 100-nm liposomes 34 . Specifically, we examined the effect of dipalmitoyl-phosphatidylcholine (DPPC) liposomes loaded with MPS and NAC on reducing lung inflammation, in the first stages of ARDS. Liposomal MPS uptake by macrophages and neutrophils can be mediated by adsorption, endocytosis, and phagocytosis 35 , where drug release occurs intra-or extracellular.

The dipalmitoyl-phosphatidylcholine (DPPC) was chosen as the main component. DPPC is a naturally occurring pulmonary surfactant, that reduces surface tension at the air-liquid interface of the alveolus, thus preventing alveolar collapse associated with inflammation [36] [37] [38] .

DPPC exerts its protective effect by integrating into plasma membrane of airway epithelium and immune cells affecting membrane integrity 38 . DPPC also acts as an immunomodulator by inhibiting cytokine release from innate immune cells in response to LPS 38 .

Liposomes are already used in clinic for treating lung disorders and injuries [39] [40] [41] . For example, an Amikacin liposome inhalation suspension (ALIS) is used for treating pulmonary infections 42 .

The proposed liposomal formulation was tested for its ability to reduce lung inflammation. Liposome's size was designed to be approximal 100nm in order to improve penetration in inflamed tissues cite 43 . The study compared between endotracheal (ET) instillation to the lungs and intravenous (IV) administration, or both routes simultaneously.

Previously, Garbuzenko et al. 44 For mucus permeation experiment for Caco-2 cells, HSPC, cholesterol and DSPE-PEG2000 and DSPE-Cy7 (0.5%) liposomes were prepared and dialyzed as described above.

Liposomal size and Zeta potential was measured using a Zetasizer Nano ZSP (Malvern Instruments, Worcestershire, UK) using appropriate polystyrene cuvettes after diluting the J o u r n a l P r e -p r o o f Detection with ELSD.

Liposomes were imaged using Cryogenic transmission electron microscopy (Cryo-TEM).

Cryo-TEM imaging was performed on a Thermo-Fisher Talos F200C, FEG-equipped high resolution-TEM, operated at 200kV. Specimens were transferred into a Gatan 626.6 cryoholder and equilibrated below -170 °C. Micrographs were recorded by a Thermo-Fisher

Falcon III direct detector camera, at a 4k x 4k resolution. Specimens were examined in TEM nanoprobe mode using Volta phase plates for contrast enhancement. Imaging was performed at a low dose mode to minimize exposure of the imaged area to electrons. Images were acquired using the Tem Imaging and Acquisition (TIA) software. Liposomes diluted x20 with saline. Cryo-TEM specimens were prepared in a controlled environment vitrification system (CEVS) 47 . Since the system under study is aqueous, preparation was done in a temperaturecontrolled chamber with humidity at saturation, to prevent evaporation of volatiles 48 .

Temperature was kept constant at 25 °C. A drop of the solution was placed on a carboncoated perforated polymer film, supported on a 200nm mesh TEM grid, mounted on tweezers.

The drop was turned into a thin film (preferably less than 300 nm) by blotting away excess solution with a metal strip covered with a filter paper. The grid was then quickly plunged into liquid ethane at its freezing point (-183 °C). Prior to specimen preparation, grids were plasma J o u r n a l P r e -p r o o f and were processed using Zen 3.4 Blue edition.

To examine in-vitro cells uptake efficiency under mucosal conditions, we developed an in-vitro mucus permeation assay using human colorectal adenocarcinoma Caco2 cell line.

These cells are naturally covered with mucus layer in the intestine and therefore act as a good model for this purpose. Mucin from the porcine stomach was dissolved to a concentration of 10mg/ml in PBS and gently shaken overnight in RT to form a disulfide bond and form mucus.

The cells were cultured separately in 24-well plates for five days, with fresh medium replacement after three days, with RPMI medium. Then, the cells were covered with 200µl of mucus to create a uniform layer on top of the cells. Since NAC breaks S-S bonds, it breaks the mucus structure. We also compared the uptake with 0.7mM concentration of NAC treatment and examined the improvement in liposomes cells uptake. Following mucus settlement on the cells, liposomes labelled with Cy7 were added to each well in 10% volume with the medium and incubated in 37 o C, 5% CO 2 with and without the NAC treatment. After two hours, the mucus and medium were removed, and the cells were washed twice with PBS. DAPI was added in 1:1000 %v/v with fresh PBS and fixed using 4% paraformaldehyde (PFA). The cells were imaged using x10 magnification with Lionheart FX automated microscope (BioTek).

Cells uptake was quantified by nuclei and liposomes fluorescence labling using Gen5 Image

Prime software (ver. 3.10, BioTek).

Mice were anesthetized with ketamine 80mg/g BW, xylazine 4.5mg/g BW and buprenorphine 100mg/g BW, intra peritoneum (ip). 20g catheter insert endotracheal (ET). To confirm tube's presence in the trachea, 60µL saline was aspirated into a syringe. The syringe was then connected to the catheter, and if the tube was in the right place, the saline bubble moved at the rate of mice breathing. LPS from Escherichia coli O26:B6 was dissolved in saline to concentration of 5mg/ml. 20µL LPS was given ET in 2 doses (with a 5 min interruption) to C57BL/6 anesthetized male mice. Lung inflammation in mice was analyzed by TNFα, IL-1α and IL-1β and IL-6, cytokines levels in BAL fluid and histology slides as described in figure 5 . The experiments described here were approved by the ethics committee (Ethical request No. IL-0470518 and IL-1020820). Acquisition was performed using the LAS-X and ZEN software, respectively.

6hr after inflammation induction (LPS ET 5mg/ml, 20µL per mouse) treatment were administered by IV (200µL), ET (20µL) or both IV and ET. The lower amount delivered ET was intended to prevent suffocation due to increased edema associated with lung inflammation treatments were DPPC liposomes, free drugs or DPPC liposomal drugs. Drug's concentrations were 4.3mg/ml and 1.1mg/ml for MPS and NAC, respectively. 26 hours after inflammation induction mice were sacrificed, and inflammation was characterized based on lung tissue histological staining (H&E) and cytokines in BAL fluid.

Mice were euthanized. 100µL of 4% natural buffer formalin (NBF) (Sigma-Aldrich) was injected into lungs via trachea. Lungs were extracted and kept in 4% NBF. Slides were cut J o u r n a l P r e -p r o o f and hematoxylin and eosin (H&E) staining was performed using Patho-Lab service. Slides were scanned using automatic slide scanner 250 flash.

Mice were euthanized by ketamine-xylazine OD and 22g catheter was inserted into mouse's trachea. 700µL of cold PBS was injected into the lungs. The lungs were gently massaged and after 30 seconds the fluid was sucked out from the lungs and kept at 4°C until cytokine analysis.

Cytokines were identified in BAL fluid supernatant or in macrophage medium to evaluate immune cell response. ELISA was carried out using PeproTech kit (900-K54, 900-K50, 900M-47, 900-K00, PeproTech Asia) protocol.

Liposomes were composed of DPPC, cholesterol and DSPE-PEG2000 50,51 at molar ratio of (60:35:5), respectively. DPPC and cholesterol were selected since they are a naturally occurring components of the pulmonary surfactant 52 ( Figure 1D ). DPPC Liposomes were loaded with both MPS and NAC, using active remote (active) loading approach 53 . For this, DPPC liposomes (102.6±0.3nm, PDI= 0.06, zeta potential=-34±10mV, Figure 1H -I) were loaded with calcium acetate (CaAcOH, 150 mM) as an osmotic pump. Drugs were actively loaded one after that other: MPS first, followed by NAC loading ( Figure 1A ). For each drug encapsulation process, different loading conditions, such as pH, drug concentration, temperature and time of incubation were examined, as detailed in Figure 1B .

Drug concentrations in the liposomes reached 4.3mg/mL and 1.1mg/mL for MPS and NAC, accordingly, with encapsulation efficiencies of 98% and 92% (%EE). Drug-to-lipid molar ratios are 7.2 and 5 for MPS and NAC, respectively. DPPC liposomal drugs particles concentration was 2.24* particle/mL, as summarized in Figure 1C .

In addition to drug encapsulation concentration, liposomes were tested for their stability and drug release profiles at physiological conditions: 50% of encapsulated NAC and 20% of the MPS released over 3 hours climbing to 60% for NAC and 90% for MPS release after 24 hours 

We examined the effect of DPPC liposomal drugs on RAW264.7 macrophages after beginning exposed to LPS. TNFα levels and Nitric oxide (NO) decreased significantly following treatment with DPPC liposomal drugs, MPS liposomes, free MPS plus NAC mix, and free MPS, in comparison to untreated LPS induced cells (Figure 2A-B) . Comparing the free drug versus the liposomal treatment demonstrates benefit or equal therapeutic influence.

Interestingly, empty DPPC liposomes showed ~25% NO decrease which may be attributed to the anti-inflammatory nature of the lipid 37,38,54 (Figure 2A-B) .

We examined the effect of NAC on liposomal mucus penetration. NAC treatments improved liposomes mucus penetration in comparison to untreated mucus ( Figure 2C ). The NAC, agent with thiol-amino structures which gives it the mucolytic feature, disrupts the disulfide bonds in the mucus 55 .

To examine the effect of NAC treatment on liposomes cells uptake under mucosal conditions, we developed an in-vitro mucus permeation assay by spreading a mucus layer over Caco2 cells followed by automated imaging of the liposomal uptake by the cells undernieth the mucus 56 ( Figure 2D ). The addition of NAC improved nanoparticle uptake by 1.8-fold, compared to cells with mucus without NAC treatment ( Figure 2E ).

The NAC dissolves the disulfide bonds of the mucus, has previously been used to remove the secreted mucus layer from cell cultures without cellular damagev 57, 58 .

Journal Pre-proof

Measuring of LPS-induced macrophage cytokine (TNFα and nitric oxide (NO)) levels following liposomes treatments. One-way ANOVA and one-tailed t-test were performed using PRISM: * P < 0.05, ** P<0.01, *** P < 0.001. Asterisk above bars connecting columns J o u r n a l P r e -p r o o f represents a significant difference between groups. C) Confocal images of 100nm liposomes of NAC treated, or untreated, mucus's penetration. D) In-vitro mucosal barrier permeation assaycells were plated on 24 walls petri dish and a layer of 200 µL synthetic mucus was applied on top of the cells as a biological barrier. The ability of nanoparticles to cross the mucus layer and be taken up by the underlying cells was quantified over time using an automated microscope setup. E) Automated microscopy images of Caco-2 cellular uptake of Cy-7 fluorescently labeled 100nm liposomes. The uptake is presented as mean±SD. One-way ANOVA with an adjusted p-value of multiple comparisons tests was used for statistical analysis; **p<0.01; *p<0.05.

Acute lung inflammation was induced via ET LPS administration as described schematically

in Figure 3A 59, 60 . Blinded pathologic assessment of mice lungs examined the inflammatory state of the lungs ( Figure 3B ). Compared to healthy lungs, LPS induced lungs had acute inflammatory infiltration with neutrophils filling the alveolar space. Vascular congestion and extravasated RBCs were also seen.

Furthermore, cytokines in BAL fluid were analyzed 6 and 26 hours after LPS induction ( Figure 3C ). IL-1α, TNF-α and IL-6 cytokine concentrations were significantly higher compared to healthy control after 6 hours (TNFα: p<0.001, IL1α: p<0.01, and IL6: p<0.001), while, at 26 hours, TNF-α, IL-1β, and IL-6 levels were higher compared to healthy control (p<0.01, p<0.0001, p<0.01, respectively), together demonstrating acute inflammation and criteria for ARDS.

J o u r n a l P r e -p r o o f 3), Dunnett's multiple comparison test **P < 0.01; **P<0.001; ***P<0.0001. Asterisk above bars connecting column represents significant difference between groups.

We tested the liposomal biodistribution to different organs at different time points To quantify the biodistribution of liposomes, Gadolinium (Gd)-loaded liposomes were administered either IV or ET and Gd content was assessed in the different organs using ICP-OES elemental analysis. Gd content in heart, liver, spleen, kidneys, and blood are displayed as injected-dose-per-organ-weight (%/g) at varying time points, Figure 4B . Gd content in lungs was normalized to the initial injected dose due to the apparent pulmonary edema observed in inflamed lungs which can alter weight measurements. In lungs, a Gd concentration of 1.09+0.09% was observed 1-hour after administration, compared to 0.240 +0.005% in healthy lungs. Moreover, a significant increase in Gd content in the healthy versus inflamed lungs was recorded 4 and 48 hours after the administration (6.5 and 8-foldincrease respectively). The Gd content in the heart, liver, spleen, kidneys, and blood was similar. In conclusion, both qualitative (IVIS) and quantitative (ICP-OES) analysis demonstrate the increased accumulation of liposomes in inflamed lungs.

Both Rhodamine-and Gd analysis exhibited a similar clearance profile ( Figure 4A-B) .

Liposomes were present in inflamed lungs even 48 hours post-injection, compared to 12 hours in healthy lungs ( Figure 4A-B Ex-vivo representative images of healthy and inflamed lungs at varying time points after IV injection of rhodamine and Gd labeled liposomes taken by whole animal IVIS imaging system. B) Biodistribution of rhodamine and Gd labeled liposomes at different time points from IV injection as measured using elemental analysis (ICP-OES) of the lungs, heart, liver, spleen, kidneys and blood. C) Ex-vivo representative IVIS images of lungs at varying time points after ET administration of rhodamine and Gd-labelled liposomes. D) Biodistribution rhodamine and Gd labeled liposomes at different time points from ET administration as measured by ICP-OES in lungs, heart, liver, spleen, kidneys and blood. Healthy mice (n =4), LPS mice (n = 3). One way ANOVA and one tailed t-test were performed using PRISM: * P < 0.05, ** P<0.01, *** P < 0.001. Asterisk above bars connecting columns represents a significant difference between groups. E) Confocal images of inflamed lung cryo-sections following Cy3-labeled liposomes administered via ET alongside Cy5-labeled liposomes administrated IV. Nuclei were stained using DAPI. Arrows exhibit high intensity of liposomes present. Arrowheads show liposomes in a blood vessel and arrows show liposomes in the airway. Scale bar=200µm.

DPPC Liposomal drugs were administered to mice 6 hours after LPS induction (LPS ET 5mg/ml, 20ࣿ µL per mouse), treatments were administered IV (200µL), ET (20µL) or both IV and ET. The lower volume delivered ET was intended to prevent suffocation. 26 hours after LPS induce, the mice were sacrificed, and inflammation was characterized by histological staining (H&E) and cytokine analysis in the BAL fluid (TNF-α and IL-6). The nanoparticle treatments reduced inflammation in the lungs, suggesting a positive effect for combined treatment ( Figure 5A ).

Histologic sections were blindly analyzed demonstrating that the untreated group present a severe acute inflammatory reaction with neutrophils filling alveolar spaces. Lungs obtained from mice treated by DPPC liposomal drugs via IV or IV and ET, showed very mild to mild inflammatory infiltration. Lungs treated with the free drug IV or ET plus IV, showed a mild inflammatory reaction. Interestingly, intravenous administration of either free drugs or DPPC liposomal drugs resulted with milder inflammatory infiltrate compared to ET administration ( Figure 5B ). The percent of severe inflammation in the alveoli relative to the total lung were analyzed histopathologically to quantify the lungs injury, demonstrating that treatment with DPPC liposomal drugs was superior in reducing lung severity (Sup. D).

To further establish the effect of the liposomal treatment, we determined the levels of TNF-α, IL-1β and IL-6 cytokines in the BAL fluid. Levels of IL-6 significantly decreased following combined IV and ET treatment compared to the untreated mice (664 pg/ml and 2962 pg/ml respectively, Figure 5C ). No significant decrease in cytokine levels was observed 26 hours after free ET or combined ET plus IV administration of drugs treatment. The levels of TNF-α J o u r n a l P r e -p r o o f significantly decreased following DPPC liposomes, liposomal drugs IV and IV plus ET administrations (322pg/ml and 540 pg/ml respectively) when compared to untreated inflamed mice (1459 pg/ml), or to mice receiving free drugs ( Figure 5C ). Similarly, the levels of tested IL-1beta were the lowest in mice that received ET plus IV treatment routes (5-fold decrease) compared to other routes.

In conclusion, while reduction in inflammation markers (TNF-α, IL-1β and IL-6) was recorded after all treatment modalities, highest reduction was observed in the combined ET plus IV administration.

J o u r n a l P r e -p r o o f TNFα, IL1β, and IL-6 levels in the BAL fluid. One-way ANOVA and one-tailed t-test were performed using PRISM: * P < 0.05, ** P<0.01, *** P < 0.001. The asterisk above bars connecting columns represents a significant difference between groups.

In this study, we developed DPPC liposomes co-loaded with the corticosteroid MPS, and the mucus active agent NAC into liposome through sequential drug loading to treat ARDS in vivo, as a model of acute lung disease.

Following systemic IV administrations, liposome accumulation was more significant in inflamed lungs in comparison to healthy lungs, indicating that liposomes exhibit preferential targeting of the inflamed lung. Local administration of liposomes via the ET route leads to a greater amount and longer retention time of liposomes in inflamed lungs.

An additional significant difference between IV and ET routes is that IV administered liposome distribution spanned across the whole lung, while ET liposomes were distributed mostly in lung parenchyma but were not found at partial distal areas of the lung.

Therefore, combining ET and IV administration modes stimulates lung accumulation in the lungs from both alveolar epithelial and endothelial blood vessel cells, allowing broad coverage of lungs.

Both in vitro free drug and liposomal treatments of Lps-stimuli macrophages showed an analogous trend for TNF-α, and NO levels decreased. It can be concluded that DPPC liposomal drugs availability is significant since effect is seen.

The iv vivo experiment demonstrated the best outcomes for IV plus ET administrations of DPPC liposomal drugs, explained by the improved lung coverage.

DPPC liposomes decreased NO levels in vitro, and TNFα levels in vivo, demonstrating some therapeutic effect of the lipid component alone. The DPPC liposomal system is a promising platform for treating lung diseases. performed using PRISM: *P < 0.05, **P<0.01, ***P < 0.001. Asterisk above bars connecting columns represents a significant difference between groups. C) Ex-vivo representative images of healthy and inflamed lungs at varying time points after IV injection of rhodamine and Gd labeled liposomes taken by whole animal IVIS imaging system. D) Quantitative presentation of H&E sections of lungs treated IV, ET or IV plus ET, with free drugs, empty DPPC liposomes or drug-loaded DPPC liposomes (n=2).

J o u r n a l P r e -p r o o f

Inflammatory mechanisms in the lung

Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults -UpToDate

The spatial landscape of lung pathology during COVID-19 progression

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States

Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment

Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome

Their Role in Innate and Adaptive Immunity

Modeling of Nanotherapy Response as a Function of the Tumor Microenvironment: Focus on Liver Metastasis

The M1 and M2 paradigm of macrophage activation: time for reassessment

Phytochemicals as modulators of M1-M2 macrophages in inflammation

Ask A Scientist: What's the Difference Between M1 and M2 Macrophages?

Their role, activation and polarization in pulmonary diseases

Regulation of nitric oxide production from macrophages by lipopolysaccharide and catecholamines

Antimicrobial mechanisms of phagocytes and bacterial evasion strategies

Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome

Glucocorticoid treatment in acute lung injury and acute respiratory distress syndrome

Methylprednisolone Infusion in Early Severe ARDS: Results of a Randomized Controlled Trial

Successful use of methylprednisolone for treating severe COVID-19

Corticosteroid use in ARDS and its application to evolving therapeutics for coronavirus disease 2019 (COVID-19): A systematic review

How corticosteroids control inflammation: Quintiles Prize Lecture

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

Corticosteroids for pneumonia

Long-term side effects of glucocorticoids

The mechanism of action of N-acetylcysteine (NAC): The emerging role of H2S and sulfane sulfur species

Mucus production stimulated by IFN-AhR signaling triggers hypoxia of COVID-19

Oxidative stress and respiratory system: pharmacological and clinical reappraisal of Nacetylcysteine

Increasing complexity and interactions of oxidative stress in chronic respiratory diseases: An emerging need for novel drug delivery systems

Role of N-acetylcysteine in the management of COPD

Effects of N-acetylcysteine treatment in acute respiratory distress syndrome: A meta-analysis

Intravenous N-acetylcysteine (NAC) for paracetamol overdose: reminder of authorised dose regimen

Impacts on Human Health. Antioxidants (Basel)

High doses of N-acetylcysteine alone or in combination with inhaled corticosteroids and oxidative stress in patients with COPD

Hydrogel systems and their role in neural tissue engineering

Liposome: classification, preparation, and applications

An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease

Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains

Surfactant Lipids at the Host-Environment Interface. Metabolic Sensors, Suppressors, and Effectors of Inflammatory Lung Disease

PEGylated liposomes: immunological responses

A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study

Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages

Using PEGylated nano-liposomes to target tissue invaded by a foreign body

Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug

Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate

Development and Validation of an Analytical Method for Related Substances in N-acetyl-L-cysteine Effervescent Tablets by RP-HPLC

Controlled environment vitrification system: An improved sample preparation technique

The Study of Nanostructured Liquids by Cryogenic-Temperature Electron Microscopy -A Status Report

Punicalagin Prevents Inflammation in LPS-Induced RAW264.7 Macrophages by Inhibiting FoxO3a/Autophagy Signaling Pathway

Structural tuning of oligonucleotides for enhanced blood circulation properties of unit polyion complexes prepared from two-branched poly(ethylene glycol)-block-poly(l-lysine)

Polysaccharide-based formulations as potential carriers for pulmonary delivery -A review of their properties and fates

The role of lipids in pulmonary surfactant

Amphipathic Weak Acid Glucocorticoid Prodrugs Remote-Loaded Into Sterically Stabilized Nanoliposomes Evaluated in Arthritic Rats and in a Beagle Dog

Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases

The chemistry and biological activities of N-acetylcysteine

Optimization of Caco-2 and HT29 co-culture in vitro cell models for permeability studies

Mucus models to evaluate the diffusion of drugs and particles

Disulfide disruption reverses mucus dysfunction in allergic airway disease

Mouse Models of Acute Lung Injury and ARDS

An Improved Method for Rapid Intubation of the Trachea in Mice

In Vivo Fluorescence Imaging of Passive Inflammation Site Accumulation of Liposomes via Intravenous Administration Focused on Their Surface Charge and PEG Modification

Vascular Bursts Act as a Versatile Tumor Vessel Permeation Route for Blood-Borne Particles and Cells

Supplementary: A) Average fluorescence intensity of signal measured in healthy (black bars) and LPSinflamed lungs (orange bars) at varying time points of rhodamine and Gd-labelled liposomes as measured by IVIS after IV injection and B) after ET administration. (A-B) Healthy mice (n =4), LPS mice (n = 3). One-way ANOVA and one-tailed t-test were

This project has received funding from the Ministry of Defense, European Union's Horizon